Sage Therapeutics (SAGE) to Release Quarterly Earnings on Tuesday

Sage Therapeutics (NASDAQ:SAGE) is scheduled to release its earnings data after the market closes on Tuesday, October 29th. Analysts expect Sage Therapeutics to post earnings of ($1.53) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.68) by ($0.02). Sage Therapeutics had a negative net margin of 458.30% and a negative return on equity of 55.87%. The business had revenue of $8.65 million during the quarter, compared to analysts’ expectations of $8.85 million. During the same quarter in the previous year, the business posted ($2.68) EPS. The company’s quarterly revenue was up 249.8% on a year-over-year basis. On average, analysts expect Sage Therapeutics to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Sage Therapeutics Stock Performance

NASDAQ SAGE opened at $8.01 on Monday. Sage Therapeutics has a one year low of $5.84 and a one year high of $28.26. The company’s 50 day moving average price is $7.53 and its 200 day moving average price is $10.10. The firm has a market capitalization of $482.06 million, a price-to-earnings ratio of -0.95 and a beta of 0.91.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Scotiabank lowered their price objective on shares of Sage Therapeutics from $19.00 to $17.00 and set a “sector outperform” rating for the company in a research report on Thursday, July 25th. Robert W. Baird lowered their price objective on shares of Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating for the company in a research report on Wednesday, October 9th. Raymond James reissued a “market perform” rating on shares of Sage Therapeutics in a research report on Thursday, October 10th. JPMorgan Chase & Co. decreased their price target on shares of Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating for the company in a research report on Tuesday, August 6th. Finally, HC Wainwright reissued a “neutral” rating and set a $25.00 price target on shares of Sage Therapeutics in a research report on Wednesday, October 9th. Two investment analysts have rated the stock with a sell rating, eighteen have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $13.76.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.